O uso terapêutico do colírio de atropina para retardar a progressão de miopia em crianças é reconhecido cientificamente e possui eficácia comprovada

2017 
The prevalence of myopia worldwide has been increasing significantly over the past decades, and it is currently a leading cause of visual impairment worldwide. This severe and significant public health problem has been addressed at the community level with the use of atropine eye drops at a concentration of 0.01% (one drop daily). This regimen appears to offer an appropriate balance between costs and benefits, indicated by a 50% reduction in the annual myopia progression rate in children without resulting in clinically significant adverse effects. The therapeutic use of atropine eye drops to slow myopia progression in children is scientifically recognized and it has been proven to be effective.
    • Correction
    • Source
    • Cite
    • Save
    • Machine Reading By IdeaReader
    0
    References
    0
    Citations
    NaN
    KQI
    []